FLML has been the subject of a number of other research reports. Leerink Swann reiterated an outperform rating and issued a $16.00 price objective on shares of Flamel Technologies SA in a report on Tuesday, September 27th. Zacks Investment Research upgraded shares of Flamel Technologies SA from a sell rating to a hold rating in a report on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $18.63.
Flamel Technologies SA (NASDAQ:FLML) opened at 12.33 on Wednesday. The firm has a market cap of $508.50 million, a PE ratio of 29.85 and a beta of 1.42. The company’s 50-day moving average is $13.66 and its 200-day moving average is $11.80. Flamel Technologies SA has a one year low of $7.56 and a one year high of $19.78.
Flamel Technologies SA (NASDAQ:FLML) last posted its earnings results on Monday, August 8th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by $0.08. The company earned $38.90 million during the quarter, compared to the consensus estimate of $32.80 million. Flamel Technologies SA had a return on equity of 25.19% and a net margin of 12.11%. The firm’s revenue was down 20.0% compared to the same quarter last year. During the same period last year, the company posted $0.34 EPS. On average, analysts forecast that Flamel Technologies SA will post ($1.08) earnings per share for the current fiscal year.
In other Flamel Technologies SA news, Director Francis Fildes sold 15,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $13.45, for a total transaction of $201,750.00. Following the completion of the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $201,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Craig R. Stapleton bought 20,000 shares of the firm’s stock in a transaction on Friday, August 26th. The shares were purchased at an average cost of $13.76 per share, with a total value of $275,200.00. Following the transaction, the director now directly owns 509,678 shares in the company, valued at approximately $7,013,169.28. The disclosure for this purchase can be found here. Company insiders own 4.45% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Falcon Point Capital LLC increased its stake in Flamel Technologies SA by 1.1% in the second quarter. Falcon Point Capital LLC now owns 1,015,841 shares of the company’s stock worth $10,910,000 after buying an additional 10,973 shares in the last quarter. Acadian Asset Management LLC increased its stake in Flamel Technologies SA by 240.2% in the second quarter. Acadian Asset Management LLC now owns 1,617,223 shares of the company’s stock worth $17,372,000 after buying an additional 1,141,783 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Flamel Technologies SA by 10.7% in the first quarter. JPMorgan Chase & Co. now owns 316,992 shares of the company’s stock worth $3,499,000 after buying an additional 30,760 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in Flamel Technologies SA during the second quarter worth $6,530,000. Finally, Janney Montgomery Scott LLC increased its stake in Flamel Technologies SA by 91.2% in the second quarter. Janney Montgomery Scott LLC now owns 221,600 shares of the company’s stock worth $2,530,000 after buying an additional 105,700 shares in the last quarter. 70.33% of the stock is owned by institutional investors and hedge funds.
About Flamel Technologies SA
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.